-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, H1nnwcNgS6oqN/pJN6/fcSnqzbwZu2QXh+8mH6kO1wR6HgCz/rSlBsQecJ48zKZn n5wOsBDugQZtbdv7pN5yNg== 0001104659-10-030413.txt : 20100524 0001104659-10-030413.hdr.sgml : 20100524 20100524161355 ACCESSION NUMBER: 0001104659-10-030413 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100520 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20100524 DATE AS OF CHANGE: 20100524 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DEPOMED INC CENTRAL INDEX KEY: 0001005201 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943229046 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-13111 FILM NUMBER: 10854116 BUSINESS ADDRESS: STREET 1: 1360 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 6504625900 MAIL ADDRESS: STREET 1: 1360 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 8-K 1 a10-10782_18k.htm 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  May 20, 2010

 

DEPOMED, INC.

(Exact name of registrant as specified in its charter)

 

001-13111

(Commission File Number)

 

California

 

94-3229046

(State or other jurisdiction of

 

(I.R.S. Employer Identification No.)

incorporation)

 

 

 

1360 O’Brien Drive, Menlo Park, California  94025

(Address of principal executive offices, with zip code)

 

(650) 462-5900

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

Depomed, Inc. (“the Company”) held its Annual Meeting of Shareholders on May 20, 2010 to consider and vote on the following proposals: (i) the election of directors until the next annual meeting of shareholders (Proposal 1); (ii) an amendment of the 2004 Equity Incentive Plan (the “2004 Plan”) to increase the number of shares of common stock issuable under the 2004 Plan by an additional 2,500,000 shares to an aggregate of 9,250,000 shares (Proposal 2); (iii) an amendment of the 2004 Employee Stock Purchase Plan (the “ESPP”) to increase the number of shares issuable under the ESPP by an additional 500,000 shares to an aggregate of 1,500,000 shares (Proposal 3); and (iv) the ratification of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2010 (Proposal 4).

 

Proposal 1:   The shareholders of Depomed elected eight directors to serve until the next annual meeting of shareholders.  The votes regarding the election of directors were as follows:

 

 

 

Votes For

 

Votes
Withheld

 

Broker Non-Votes

 

Peter D. Staple.

 

28,960,958

 

79,152

 

15,209,436

 

G. Steven Burrill

 

28,921,745

 

118,365

 

15,209,436

 

Karen A. Dawes

 

28,961,158

 

78,952

 

15,209,436

 

Carl A. Pelzel

 

28,072,404

 

967,706

 

15,209,436

 

James A. Schoeneck

 

28,960,663

 

79,447

 

15,209,436

 

Craig R. Smith, M.D

 

28,487,839

 

552,271

 

15,209,436

 

Julian N. Stern

 

28,075,287

 

964,823

 

15,209,436

 

David B. Zenoff, D.B.A.

 

28,804,876

 

235,234

 

15,209,436

 

 

Proposal 2:  The shareholders of Depomed approved the amendment of the 2004 Plan to increase the number of shares of common stock issuable under the 2004 Plan by an additional 2,500,000 shares to an aggregate of 9,250,000 shares with the following votes:

 

For

 

26,674,952

 

Against

 

2,251,019

 

Abstain

 

114,139

 

Broker Non-Votes

 

15,209,436

 

 

Proposal 3:  The shareholders of Depomed approved the amendment of the ESPP to increase the number of shares issuable under the ESPP by an additional 500,000 shares to an aggregate of 1,500,000 shares with the following votes:

 

For

 

27,559,829

 

Against

 

1,472,424

 

Abstain

 

7,857

 

Broker Non-Votes

 

15,209,436

 

 

Proposal 4:  The shareholders of Depomed approved the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2010 with the following votes:

 

For

 

43,886,297

 

Against

 

354,878

 

Abstain

 

8,371

 

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

DEPOMED, INC.

 

 

 

 

 

 

Date: May 24, 2010

By:

/s/ Matthew M. Gosling

 

 

Matthew M. Gosling

 

 

Vice President and General Counsel

 

3

 -----END PRIVACY-ENHANCED MESSAGE-----